علاج ساركوما الغلاف الزليلي في البالغين (العمر 18 عامًا فأكثر)

References

DOI: 10.1016/j.esmoop.2023.101618

• Five-year survival rates in adults with SS have plateaued since the 1980s with no advances in treatment efficacy.
• For example, in patients treated with ifosfamide combination therapy, high-dose single-agent ifosfamide infusions over 4-5 or 14 days can be administered.
• In advanced SS treated with trabectedin, median PFS and OS were 5.6 and 14.3 months, respectively.
• Another retrospective study assessing adult patients 24 years of age with refractory STS showed that dacarbazine as a second-line treatment achieved no CRs and a median PFS of 2 months.
• Pazopanib is also approved for the treatment of adult advanced STS from the second line.